PDCD1 and neoplasm: A study has found that CAR-T cells produced by Th/Tc17 cells could improve the persistence ability and tumor-suppressive role of CAR-T cells in the TME when the stimulator of STING agonists DMXAA or cGAMP were combined with anti-PD-1 antibodies.